Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance

ADMA Biologics IncTrade
JPMorgan Diversified Return International Eqty ETFTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while JPMorgan Diversified Return International Eqty ETF trades at $77. The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.

ADMAJPIN
Market Cap
$2.22B
Sector
Health
52-Week High
$20.38$77.00
52-Week Low
$7.60$64.96
Enterprise Value
$2.29B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.

The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.

JPMorgan Diversified Return International Eqty ETF

JPIN (JPMorgan Diversified Return International Equity ETF) trades at $76.97, up 0.8% with strong technical momentum as moving averages signal bullish conditions. The ETF provides broad exposure to foreign large-cap value stocks through a smart beta approach. Recent dividend activity shows a $0.91 distribution scheduled for June 2026, while technical indicators show mixed signals with RSI in overbought territory but ADX confirming strong trend strength.

The ETF's outlook remains positive given its diversified international exposure and value orientation, though investors face currency risk and emerging market volatility. Current technical strength suggests continued upward momentum, but overbought RSI levels indicate potential near-term consolidation. The fund's systematic approach to international value investing provides defensive characteristics in volatile markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About JPMorgan Diversified Return International Eqty ETF

The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.

Read more on JPIN